ReviewExploration of targeted anti-tumor therapy2021

Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC.

Luca Cantini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.